Investing

Annexon : ANNX

ANNX

Stock Data

$5.75

$0.12 (2.04%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Annexon Inc is a pioneering biopharmaceutical firm focused on developing treatments for autoimmune, neurodegenerative, and eye diseases. Leveraging its expertise in the classical complement pathway, particularly the C1q molecule, Annexon is advancing a portfolio of therapies aimed at addressing complex conditions like Guillain-Barré syndrome, Huntington's disease, and lupus nephritis. With its lead candidates in various stages of clinical trials, including monoclonal antibodies and oral small molecules, Annexon is at the forefront of targeting diseases with significant unmet medical needs. Founded in 2011, the company is based in Brisbane, California.

All Annexon Articles

1 Article

Lee Jackson | Dec 23, 2025 at 8:13 AM EST

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More

Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of…